PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33406639-8 2021 Moreover, SGK1 activation induces the phosphorylation of NF-kappaB p65, and an NF-kappaB inhibitor enhances the sensitivity of KMS-20 cells to bortezomib and ixazomib. ixazomib 158-166 nuclear factor kappa B subunit 1 Homo sapiens 57-66 33406639-10 2021 These results indicate that the activation of the SGK1/NF-kappaB pathway correlates with a low sensitivity to bortezomib and ixazomib, and a combination of bortezomib and ixazomib with an SGK1 or NF-kappaB inhibitor may be involved in the treatment of MM via activation of the SGK1/NF-kappaB pathway. ixazomib 125-133 nuclear factor kappa B subunit 1 Homo sapiens 55-64 33406639-10 2021 These results indicate that the activation of the SGK1/NF-kappaB pathway correlates with a low sensitivity to bortezomib and ixazomib, and a combination of bortezomib and ixazomib with an SGK1 or NF-kappaB inhibitor may be involved in the treatment of MM via activation of the SGK1/NF-kappaB pathway. ixazomib 171-179 nuclear factor kappa B subunit 1 Homo sapiens 55-64 33406639-10 2021 These results indicate that the activation of the SGK1/NF-kappaB pathway correlates with a low sensitivity to bortezomib and ixazomib, and a combination of bortezomib and ixazomib with an SGK1 or NF-kappaB inhibitor may be involved in the treatment of MM via activation of the SGK1/NF-kappaB pathway. ixazomib 171-179 nuclear factor kappa B subunit 1 Homo sapiens 196-205 33406639-10 2021 These results indicate that the activation of the SGK1/NF-kappaB pathway correlates with a low sensitivity to bortezomib and ixazomib, and a combination of bortezomib and ixazomib with an SGK1 or NF-kappaB inhibitor may be involved in the treatment of MM via activation of the SGK1/NF-kappaB pathway. ixazomib 171-179 nuclear factor kappa B subunit 1 Homo sapiens 196-205 32350909-0 2020 Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-kappaB pathway activation. ixazomib 20-28 nuclear factor kappa B subunit 1 Homo sapiens 100-109 32350909-6 2020 CONCLUSIONS: Adding ixazomib to Rd provides clinical benefit in MM tumors with increased non-canonical NF-kappaB pathway activity. ixazomib 20-28 nuclear factor kappa B subunit 1 Homo sapiens 103-112 30487243-11 2019 IMPLICATIONS: This preclinical study supports the use of oral proteasome inhibitor ixazomib for targeting NF-kappaB signaling in the treatment of EBV-associated B-cell neoplasms.Visual Overview: http://mcr.aacrjournals.org/content/molcanres/17/4/839/F1.large.jpg. ixazomib 83-91 nuclear factor kappa B subunit 1 Homo sapiens 106-115 29699990-12 2018 Finally, a potential therapeutic application of proteasome inhibitors (bortezomib and ixazomib), which are known to inhibit NF-kappaB, was identified through their ability to decrease proliferation and increase apoptosis in LGL leukemia cell lines and primary patient cells. ixazomib 86-94 nuclear factor kappa B subunit 1 Homo sapiens 124-133